People: Clovis Oncology Inc (CLVS.OQ)
CLVS.OQ on NASDAQ Stock Exchange Global Select Market
77.36USD
1 Aug 2013
77.36USD
1 Aug 2013
Price Change (% chg)
$-0.52 (-0.67%)
$-0.52 (-0.67%)
Prev Close
$77.88
$77.88
Open
$79.25
$79.25
Day's High
$81.75
$81.75
Day's Low
$74.03
$74.03
Volume
135,728
135,728
Avg. Vol
103,511
103,511
52-wk High
$86.29
$86.29
52-wk Low
$11.19
$11.19
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Patrick Mahaffy |
49 | 2009 | President, Chief Executive Officer, Director |
Erle Mast |
49 | 2009 | Chief Financial Officer, Executive Vice President |
Andrew Allen |
45 | 2009 | Executive Vice President - Clinical and Pre-Clinical Development, Chief Medical Officer |
Gillian Ivers-Read |
59 | 2009 | Executive Vice President - Technical Operations, Chief Regulatory Officer |
Steven Hoerter |
41 | 2011 | Senior Vice President - Commercial |
Keith Flaherty |
2013 | Director | |
Ginger Graham |
56 | 2013 | Director |
Brian Atwood |
59 | 2009 | Independent Director |
M. James Barrett |
2009 | Independent Director | |
James Blair |
2009 | Independent Director | |
Paul Klingenstein |
57 | 2009 | Independent Director |
Edward McKinley |
59 | 2009 | Independent Director |
Thorlef Spickschen |
72 | 2009 | Independent Director |
Biographies
| Name | Description |
|---|---|
Patrick Mahaffy |
Mr. Patrick J. Mahaffy is the President, Chief Executive Officer, Director of Clovis Oncology, Inc since inception, April 20, 2009. He is one of the co-founders. Previously, Mr. Mahaffy served as President and Chief Executive Officer and as a member of the board of directors at Pharmion Corporation, which he founded in 2000 and sold to Celgene Corporation in 2008. From 1992 through 1998, Mr. Mahaffy was President and Chief Executive Officer of NeXagen, Inc. and its successor, NeXstar Pharmaceuticals, Inc., a biopharmaceutical company. Prior to that, Mr. Mahaffy was a Vice President at the private equity firm E.M. Warburg Pincus and Co. Mr. Mahaffy also serves on the boards of directors of Orexigen Therapeutics, Inc. (NASDAQ: OREX) and Flexion Therapeutics, Inc. He is also a trustee of Lewis and Clark College. Mr. Mahaffy has a B.A. in international affairs from Lewis and Clark College and a M.A. in international affairs from Columbia University. |
Erle Mast |
Mr. Erle T. Mast is the Chief Financial Officer, Executive Vice President of Clovis Oncology, Inc since inception, April 20, 2009. He is one of the co-founders. Previously, Mr. Mast served in the same role at Pharmion Corporation, beginning in 2002. From 1997 through 2002, Mr. Mast worked for Dura Pharmaceuticals, Inc. and its successor, Elan Corporation. From 2000 to 2002, he served as Chief Financial Officer for the Global Biopharmaceuticals business unit for Elan. From 1997 to 2000, Mr. Mast served as Vice President of Finance for Dura Pharmaceuticals. Prior to that, Mr. Mast was a partner with Deloitte & Touche, LLP. Mr. Mast also serves on the boards of directors of Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) and Zogenix, Inc. (NASDAQ: ZGNX). Mr. Mast received a B.Sc. in business administration from California State University Bakersfield. |
Andrew Allen |
Dr. Andrew R. Allen, Ph.D., is the Executive Vice President - Clinical and Pre-Clinical Development, Chief Medical Officer of Clovis Oncology, Inc., since inception, April 20, 2009. He is one of the co-founders. Previously, Dr. Allen served in the same role at Pharmion Corporation, beginning in 2006. From 2004 through 2006, Dr. Allen served as Vice President of BioPharma Development and Head of the Oncology Therapeutic Unit for Chiron Corporation. Previously, Dr. Allen served as global project head in Abbott Laboratories’ oncology franchise, and prior to that he progressed through positions of increasing responsibility at the management consulting firm McKinsey & Company, with a focus on oncology strategy. Dr. Allen serves on the board of directors of Nodality, Inc., a privately-held biotechnology company. Dr. Allen qualified in medicine at Oxford University and earned his Ph.D. from the Imperial College of Science, Technology and Medicine in London. Dr. Allen also obtained post-graduate internal medicine qualification as a Member of Royal College of Physicians (MRCP). |
Gillian Ivers-Read |
Dr. Gillian C. Ivers-Read is the Executive Vice President - Technical Operations, Chief Regulatory Officer of Clovis Oncology, Inc since inception, April 20, 2009. She is one of the co-founders. Previously, Ms. Ivers-Read served as Executive Vice President, Development Operations at Pharmion Corporation, beginning in 2002. From 1996 to 2001, Ms. Ivers-Read held various regulatory positions with Hoechst Marion Roussel and its successor, Aventis Pharmaceuticals, Inc., where she most recently held the position of Vice President, Global Regulatory Affairs. From 1994 to 1996, Ms. Ivers-Read was Vice President, Development and Regulatory Affairs for Argus Pharmaceuticals, and from 1984 to 1994, she served as a regulatory affairs director for Marion Merrell Dow. Ms. Ivers-Read serves on the board of Bio-Path Holdings, Inc. (OTC BB: BPTH). Ms. Ivers-Read received a B.Sc. in pharmacology from University College London. |
Steven Hoerter |
Mr. Steven L. Hoerter is Senior Vice President - Commercial of Clovis Oncology, Inc., since August 2011. From 2010 to 2011, Mr. Hoerter was General Manager and Management Center Head at Hoffmann-LaRoche Ltd. for the Sub-Saharan Africa and Indian Ocean Region, based in Johannesburg, South Africa. From 2005 to 2010, Mr. Hoerter held a variety of positions at Genentech, Inc., including serving on the senior leadership team for Genentech’s BioOncology business as Senior Director, Pipeline Development and Commercial Operations. Prior to that he worked at Chiron Corporation and Eli Lilly and Company. During Mr. Hoerter’s 11-year career at Lilly, he held positions in sales, business development, marketing and business unit management in the US, Europe and Africa. Mr. Hoerter has a B.A. in Russian and Political Science from Bucknell University, an M.B.A. from Tilburg University and a M.S. in Management from Purdue University. |
Keith Flaherty |
Dr. Keith Flaherty, M.D., is Director of Clovis Oncology, Inc. He is an Associate Professor of Medicine at Harvard Medical School, Associate Physician of Medicine, Hematology/Oncology at Massachusetts General Hospital, and Director of the Henri and Belinda Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center. Dr. Flaherty is also the Deputy Chair for Biomarker Sciences and the Chair of the Developmental Therapeutics Committee in the Eastern Cooperative Oncology Group. Dr. Flaherty has served as Principal Investigator for numerous first-in-human clinical trials with novel, targeted therapies, including the first in-human trials of the first prospectively developed selective BRAF inhibitors for metastatic melanoma. Dr. Flaherty has a Bachelor of Science from Yale University and medical degree from Johns Hopkins University. Dr. Flaherty trained in internal medicine at Brigham and Women's Hospital and completed a medical oncology fellowship at the University of Pennsylvania. |
Ginger Graham |
Ms. Ginger L. Graham is Director of Clovis Oncology, Inc. Ginger is the President and CEO of Two Trees Consulting, where she coaches first-time CEOs of public and private companies. For the last four years, she has been a senior lecturer at Harvard University and a faculty member in its Entrepreneurship Unit. Ms. Graham is the former President and CEO of Amylin Pharmaceuticals, a biopharmaceutical company based in San Diego, CA focused on diabetes and obesity. Previously, Ms. Graham was Group Chairman, Office of the President for Guidant Corporation. Ms. Graham serves on the Boards of Directors for Walgreen Co., Genomic Health, Inc., Surefire Medical, Elcelyx Therapeutics Inc., Proteus Biomedical and Circle of Life Hospice Foundation. Ms. Graham has a Bachelor of Science, Agriculture with high honors from the University of Arkansas and a Master in Business Administration with distinction from Harvard Business School. |
Brian Atwood |
Mr. Brian G. Atwood is an Independent Director of Clovis Oncology, Inc since inception, April 20, 2009. In 1999, he co-founded and currently serves as a Managing Director for Versant Ventures, a healthcare-focused venture capital firm. Prior to founding Versant Ventures, Mr. Atwood served as a general partner of Brentwood Associates, a venture capital firm. Mr. Atwood also serves on the boards of several pharmaceutical and biotechnology companies, including Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), Five Prime Therapeutics, Immune Design Corp., Groove Biopharma Corporation (formerly known as Mirina Corporation), OpGen, Inc., PhaseRx, Inc., Spark Diagnostics, Trius Therapeutics, Inc. (NASDAQ: TSRX) and Veracyte, Inc. Mr. Atwood also served on the board of Pharmion Corporation from January 2000 until the company’s acquisition in 2008. Mr. Atwood holds a B.S. in biological sciences from the University of California, Irvine, a M.S. in ecology from the University of California, Davis, and an M.B.A. from Harvard University. |
M. James Barrett |
Dr. M. James Barrett, Ph.D., is an Independent Director of Clovis Oncology, Inc since inception, April 20, 2009. Since September 2001, he has served as a general partner of New Enterprise Associates Inc., a venture capital firm focusing on the healthcare, information technology and energy technology industries. From 1997 to 2001, Dr. Barrett served as Chairman and Chief Executive Officer of Sensors for Medicine and Science, which he founded in 1997. Dr. Barrett serves on the boards of several pharmaceutical and biotechnology companies, including Amicus Therapeutics, Inc. (NASDAQ: FOLD), Blend Biosciences, Inc., Cardioxyl Pharmaceuticals, Inc., GlycoMimetics, Inc., PhaseBio Pharmaceuticals, Inc., Predictive Biosciences, Inc., Psyadon Pharmaceuticals, Inc. (formerly known as Ruxton Pharmaceuticals, Inc.), Roka Bioscience, Inc., Supernus Pharmaceuticals, Inc., Targacept, Inc. (NASDAQ: TRGT), and Zosano Pharma, Inc., as well as continuing to serve as Chairman of Sensors for Medicine and Science. Dr. Barrett previously served on the board of, among others, YM Biosciences, Inc. (NYSE AMEX: YMI), and also served on the board of Pharmion Corporation from December 2001 until the company’s acquisition in 2008. Dr. Barrett received a Ph.D. in biochemistry from the University of Tennessee, his M.B.A. from the University of Santa Clara, and a B.S. in chemistry from Boston College. |
James Blair |
Dr. James C. Blair, Ph.D., is an Independent Director of Clovis Oncology, Inc since inception, April 20, 2009. Since 1985, he has served as a general partner of Domain Associates, L.L.C., a venture capital management company focused on life sciences. Dr. Blair currently serves on the boards of Applied Proteomics, Inc., Astute Medical, Inc., aTyr Pharma, Inc., Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), CoDa Therapeutics, Inc., IntegenX, Inc., Meritage Pharma Inc., NeuroPace, Inc., and Zogenix, Inc. (NASDAQ: ZGNX). He has previously served on the boards of over 40 life science ventures including Amgen Inc. (NASDAQ: AMGN), Aurora Biosciences Corp., Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN), Applied Biosystems Inc., Dura Pharmaceuticals, Inc., Nuvasive, Inc. (NASDAQ: NUVA), and Volcano Corporation (NASDAQ: VOLC). Dr. Blair served on the board of Pharmion Corporation from January 2000 until the company’s acquisition in 2008. Dr. Blair currently serves on the board of directors of the Prostate Cancer Foundation, and he is on the advisory boards of the Department of Molecular Biology at Princeton University, the USC Stevens Institute for Innovation, the Division of Chemistry and Chemical Engineering at the California Institute of Technology and the California Institute of Technology Innovation Initiative. He received a B.S.E. from Princeton University and M.S.E. and Ph.D. degrees from the University of Pennsylvania, all in electrical engineering. |
Paul Klingenstein |
Mr. Paul H. Klingenstein is an Independent Director of Clovis Oncology, Inc since inception, April 20, 2009. He is the Managing Partner of Aberdare Ventures, a healthcare-focused venture capital firm he formed in 1999. Prior to founding Aberdare, Mr. Klingenstein worked in venture capital and private equity with Warburg Pincus and Accel Partners, and was an advisor to the Rockefeller Foundation. Mr. Klingenstein currently serves on the boards of Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC) and EnteroMedics Inc. (NASDAQ: ETRM). Mr. Klingenstein has previously served on the boards of Ablation Frontiers, Inc., Alibris, Ample Medical Corporation, Aviron, Conatus Pharmaceuticals Inc., EP Technologies, Glycomed Inc., Idun Pharmaceuticals Inc., Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), Nevro Corp., Pharmion Corp., Posit Science Corporation, U.S. Behavioral Health, VertiFlex Inc., Viagene Inc., and Xomed Surgical Products Inc. He is currently the Chairman of the Board of the International AIDS Vaccine Initiative, and is an advisory board member of the University of California Berkeley School of Public Health. He has also served on the boards of various educational and non-profit institutions. Mr. Klingenstein received an A.B. in anthropology from Harvard University and an M.B.A. from Stanford University. |
Edward McKinley |
Mr. Edward J. McKinley is an Independent Director of Clovis Oncology, Inc since inception, April 20, 2009. Mr. McKinley spent 20 years serving in various roles at the private equity firm Warburg Pincus, including managing the firm’s private equity activity in Europe and serving on the firm’s Management Committee. Before joining Warburg Pincus, he was with the management consulting firm McKinsey & Company. Mr. McKinley also served on the board of Pharmion Corporation from October 2004 until the company’s acquisition in 2008 and currently serves and on the boards of several private companies, and as an advisor or investment committee head for several investment management firms. He also serves on the investment committee of several endowments, and on the boards or advisory boards of several non-profit organizations. He graduated Phi Beta Kappa with honors from Stanford University and holds a graduate management degree from Yale University. |
Thorlef Spickschen |
Dr. Thorlef Spickschen is an Independent Director of Clovis Oncology, Inc since inception, April 20, 2009. From 1994 to 2001, Dr. Spickschen was chairman and Chief Executive Officer of BASF Pharma/Knoll AG. From 1984 to 1994, Dr. Spickschen worked with Boehringer Mannheim GmbH, where he was responsible for sales and marketing and has been Chairman of its Executive Board since 1990. From 1976 to 1984, Dr. Spickschen was Managing Director, Germany and Central Europe for Eli Lilly & Co. Dr. Spickschen is currently Chairman of BIOTEST AG, a publicly traded company in Germany and on the board of Cytos Biotechnology AG, which is publicly-traded in Switzerland. Dr. Spickschen also served on the board of Pharmion Corporation from December 2001 through the company’s acquisition in 2008. Dr. Spickschen received a Doctorate in business management from the University of Cologne. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Patrick Mahaffy |
1,125,360 |
Erle Mast |
649,967 |
Andrew Allen |
682,013 |
Gillian Ivers-Read |
659,676 |
Steven Hoerter |
865,184 |
Keith Flaherty |
-- |
Ginger Graham |
-- |
Brian Atwood |
-- |
M. James Barrett |
-- |
James Blair |
-- |
Paul Klingenstein |
-- |
Edward McKinley |
-- |
Thorlef Spickschen |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
Patrick Mahaffy |
328,125 | 347,813 |
Erle Mast |
109,375 | 115,938 |
Andrew Allen |
109,375 | 115,937 |
Gillian Ivers-Read |
109,375 | 115,937 |
Steven Hoerter |
0 | 0 |
Keith Flaherty |
0 | 0 |
Ginger Graham |
0 | 0 |
Brian Atwood |
0 | 0 |
M. James Barrett |
0 | 0 |
James Blair |
0 | 0 |
Paul Klingenstein |
0 | 0 |
Edward McKinley |
0 | 0 |
Thorlef Spickschen |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
ALLEN ANDREW R |
2,500 | $68.84 |
ALLEN ANDREW R |
2,600 | $70.72 |
ALLEN ANDREW R |
6,494 | $67.65 |
ALLEN ANDREW R |
700 | $65.77 |
ALLEN ANDREW R |
5,800 | $70.06 |
ALLEN ANDREW R |
4,500 | $66.89 |
HOERTER STEVEN L |
10,000 | $73.06 |
DP VII ASSOCIATES L P |
2,779 | $64.58 |
HOERTER STEVEN L |
10,000 | $11.02 |
BARRETT MICHAEL JAMES |
2,483 | $70.80 |
DOMAIN PARTNERS VII L P |
159,192 | $64.58 |
ATWOOD BRIAN G |
1,142 | $0.00 |
DRANT RYAN D |
2,483 | $0.00 |
DRANT RYAN D |
11,399 | $0.00 |
SANDELL SCOTT D |
1,139,890 | $0.00 |
BARRIS PETER J |
2,483 | $0.00 |
KOLLURI KRISHNA KITTU |
77 | $0.00 |
VERSANT VENTURE CAPITAL IV L P |
3,400 | $0.00 |
KERINS PATRICK J |
575 | $0.00 |
SANDELL SCOTT D |
11,399 | $0.00 |
MOTT DAVID M |
575 | $0.00 |
WELLER HARRY R |
1,139,890 | $0.00 |
BASKETT FOREST |
494 | $0.00 |
VISWANATHAN RAVI |
383 | $0.00 |
MOTT DAVID M |
1,139,890 | $0.00 |

